How do you pay?

How to pay the least

Ask for the cash price

Orenitram

We didn’t find one.

  1. Ask your pharmacy for Orenitram’s cash price, and one or two other pharmacies too.
  2. Orenitram’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameOrenitram
Authorized generictreprostinil
Regular generictreprostinil
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Orenitram?
The original
–
–

Brand nameThe maker’s card

United Therapeutics Cares Co-Pay Assistance Program

Savings card from United Therapeutics

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Sign up on orenitram.com 

Or call 1-844-864-8437.

In the maker’s words

“With the United Therapeutics Cares Co-Pay Assistance Program, most eligible patients pay as little as a $0 co-pay for Orenitram.”

From the maker’s offer on orenitram.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Orenitram itself, from the same company, sold without the brand name, and usually for less. For now Orenitram is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

Orenitram is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):

  • To delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

Source: the FDA label for Orenitram (United Therapeutics Corporation), November 20, 2024. Full label on DailyMed 

Good to know